Liraglutide is a GLP-1 analog, which is resistant to degradation. Phase III trials have demonstrated that liraglutide effectively controls glucose levels, while reducing bodyweight.

Obesity drug developers Structure Therapeutics (NASDAQ ... Indiana-based pharma giant reported Phase 3 data for its oral GLP-1 agonist orforglipron in type 2 diabetes. While LLY said that the ...